The demographic and clinical information (including CSF levels of Aβ42, Aβ40, total tau and ptau181) of subjects with CSF samples (AD, n=25; EC, n=26) are presented in Supplementary Table 1. This evidence concerns the gene MAPT and Alzheimer disease.